Avalon GloboCare Corp (NASDAQ:ALBT) said Thursday that it joined the Advanced Micro Devices, Inc (NASDAQ:AMD) AI Developer Program to strengthen its artificial intelligence capabilities, while continuing to advance its health-tech product rollout.
AMD AI Developer Program Access
Avalon said the AMD AI Developer Program will provide access to AMD Developer Cloud credits, advanced development tools, training, and community resources to accelerate AI development.
The company plans to use these resources primarily through its AI-focused subsidiary, Avalon Quantum AI LLC (AQAI), as it scales automated commentary video generation systems, develops enterprise documentation tools, and builds an AI-powered workflow automation platform.
Through the program, Avalon will gain access to high-performance computing powered by AMD Instinct accelerators and EPYC processors.
The company expects these tools to improve model training efficiency, speed up inference, and support the scalability of large language and multimodal AI systems used by AQAI.
AQAI Platform Expansion
AQAI is developing AI systems designed for automated, evidence-constrained commentary video generation, AI-assisted drafting for public company communications, enterprise-grade compliance and workflow automation, and adaptive content creation tailored to specific audiences.
KetoAir Commercialization Plans
Separately, Avalon renewed its U.S. Food and Drug Administration establishment registration for KetoAir, its handheld breathalyzer designed for ketogenic health management, in January.
KetoAir measures breath acetone concentration (BrAce), a biomarker associated with fat metabolism and nutritional ketosis, and uses nano-sensor technology to deliver real-time, non-invasive metabolic readings.
The device targets consumers pursuing ketogenic diets for weight management, athletic performance, and therapeutic or lifestyle programs.
Avalon designed KetoAir to integrate with iOS and Android smartphones through companion apps available in the Apple Inc (NASDAQ:AAPL) App Store and Alphabet Inc (NASDAQ:GOOGL) Google Play Store.
The company plans to market the device through both business-to-business and business-to-consumer channels, with AQAI supporting marketing and distribution efforts.
Avalon expects to begin marketing initiatives in the second quarter of 2026.
ALBT Price Action: Avalon Globocare shares were down 0.61% at $0.50 during premarket trading on Thursday. The stock is trading near its 52-week low of $0.42, according to Benzinga Pro data.
Photo via Shutterstock
